Company Overview
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Why Investors Should Care
Operating margin of 22.9% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.37.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $24.57B (+2.9% YoY); net profit $3.61B.
- Trailing 12 Months Year-on-year growth — revenue +3.7%, earnings +9.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.5%, profit CAGR 5.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.55% |
| 1 Year: | 3.70% |
Compounded Profit Growth
| 5 Years: | 5.54% |
| 1 Year: | 9.80% |
Stock Price Performance
| 1 Year: | +2.29% |
| 6 Months: | -15.63% |
| 3 Months: | +1.31% |
| 1 Month: | +11.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)64.56 · Neutral
P/E of 39.06 is above the sector median of 25.88 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DHR Danaher Corporation SPX | 200.79 | 39.06 | $142.11B | 0.80% | 6.12% | 7.08% | 4.55% | 5.54% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2015 | Oct 2015 | Dec 2015 | Apr 2016 | Jul 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Apr 2020 | Jul 2020 | Oct 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 4.02B | 4.25B | 4.17B | 4.60B | 4.22B | 4.44B | 4.38B | 4.87B | 4.34B | 5.30B | 5.88B | 6.86B | 7.22B | 7.23B | 6.53B | 6.53B | 6.46B | 7.13B | 5.95B | 5.91B | 5.62B | 6.41B | 5.80B | 5.74B | 5.80B | 5.74B | 5.94B | 6.05B | 5.95B |
| Gross Profit | 1.88B | 1.89B | 2.26B | 2.17B | 2.38B | 2.29B | 2.50B | 2.33B | 2.48B | 2.54B | 2.84B | 2.27B | 2.39B | 2.31B | 2.53B | 2.35B | 2.48B | 2.44B | 2.70B | 2.44B | 2.85B | 3.23B | 4.25B | 4.40B | 4.36B | 4.06B | 4.01B | 3.89B | 4.23B | 3.66B | 3.32B | 3.27B | 3.78B | 3.49B | 3.43B | 3.40B | 3.51B | 3.52B | 3.52B | 3.59B |
| Operating Income | 582.90M | 480.00M | 651.60M | 613.10M | 710.10M | 699.10M | 728.60M | 617.00M | 676.70M | 759.20M | 937.50M | 687.50M | 758.90M | 745.30M | 863.40M | 719.70M | 811.70M | 776.30M | 961.70M | 698.00M | 844.00M | 1.09B | 2.00B | 2.00B | 1.31B | 1.93B | 1.89B | 1.72B | 2.00B | 1.52B | 1.16B | 1.19B | 1.34B | 1.31B | 1.17B | 958.00M | 1.27B | 760.00M | 1.15B | 1.34B |
| Net Income | 695.70M | 1.40B | 688.60M | 758.40M | 656.70M | 391.60M | 747.00M | 506.10M | 557.30M | 572.10M | 856.60M | 566.60M | 673.80M | 663.70M | 746.80M | 333.80M | 731.30M | 668.00M | - | 595.00M | 927.00M | 883.00M | 1.70B | 1.78B | 1.16B | 1.73B | 1.68B | 1.57B | - | 1.45B | 1.11B | 1.13B | - | 1.09B | 907.00M | 818.00M | 954.00M | 555.00M | 908.00M | 1.03B |
| Diluted EPS | 0.97 | 2.01 | 0.99 | 1.09 | 0.94 | 0.56 | 1.07 | 0.72 | 0.79 | 0.81 | 1.21 | 0.80 | 0.95 | 0.93 | 1.05 | 0.46 | 0.97 | 0.89 | 1.73 | 0.81 | 1.24 | 1.16 | 2.29 | 2.40 | 1.54 | 2.31 | 2.25 | 2.10 | 2.99 | 1.94 | 1.49 | 1.51 | 1.45 | 1.45 | 1.22 | 1.12 | 1.32 | 0.77 | 1.27 | 1.45 |
| R&D Expense | 304.60M | 212.20M | - | 226.10M | 239.90M | 241.10M | - | 267.40M | 283.30M | 279.20M | - | 298.70M | 311.70M | 301.20M | - | 267.50M | 282.10M | 282.60M | - | 287.00M | 323.00M | 342.00M | 380.00M | 426.00M | 441.00M | 441.00M | 431.00M | 420.00M | - | 373.00M | 361.00M | 362.00M | - | 368.00M | 391.00M | 383.00M | 379.00M | 403.00M | 378.00M | 387.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.03B | 12.70B | 10.52B | 12.55B | 16.09B | 18.26B | 18.28B | 12.87B | 14.43B | 16.88B | 15.52B | 17.05B | 17.91B | 22.28B | 24.80B | 26.64B | 23.89B | 23.88B | 24.57B |
| Gross Profit | - | 5.94B | 5.07B | 6.40B | 8.18B | 9.41B | 9.34B | 6.85B | 7.77B | 9.33B | 8.57B | 9.51B | 9.98B | 12.47B | 15.24B | 16.19B | 14.03B | 14.21B | 14.52B |
| Operating Income | 1.74B | 1.87B | 1.44B | 2.05B | 2.62B | 3.17B | 3.12B | 2.04B | 2.16B | 2.74B | 2.57B | 3.06B | 3.27B | 4.23B | 6.38B | 7.54B | 5.20B | 4.86B | 4.69B |
| Net Income | 1.37B | 1.32B | 1.15B | 1.79B | 2.17B | 2.39B | 2.69B | 2.60B | 3.36B | 2.55B | 2.49B | 2.65B | 3.01B | 3.65B | 6.43B | 7.21B | 4.76B | 3.90B | 3.61B |
| Diluted EPS | 4.19 | 1.98 | 1.73 | 2.64 | 3.11 | 3.36 | 3.80 | 3.63 | 4.74 | 3.65 | 3.53 | 3.74 | 4.05 | 4.89 | 8.61 | 9.66 | 6.38 | 5.29 | 5.05 |
| R&D Expense | 601.42M | 725.44M | 600.27M | 774.00M | 1.02B | 1.14B | 1.10B | 769.40M | 861.40M | 975.10M | 956.40M | 1.06B | 1.13B | 1.35B | 1.50B | 1.53B | 1.50B | 1.58B | 1.60B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 17.49B | 19.60B | 22.22B | 29.95B | 32.94B | 34.67B | 36.99B | 48.22B | 45.30B | 46.65B | 47.83B | 62.08B | 76.16B | 83.18B | 84.35B | 84.49B | 77.54B | 83.46B |
| Total Equity | - | - | 9.81B | 11.63B | 13.71B | 16.90B | 19.02B | 22.39B | 23.38B | 23.69B | 23.00B | 26.36B | 28.21B | 30.27B | 39.77B | 45.17B | 50.08B | 53.49B | 49.54B | 52.53B |
| Cash & Equivalents | 317.81M | 239.11M | 392.85M | 1.72B | 1.63B | 537.00M | 1.68B | 3.12B | 3.01B | 790.80M | 963.70M | 630.30M | 787.80M | 19.91B | - | - | - | - | - | - |
| Long Term Debt | - | - | 2.55B | 2.89B | 2.78B | 5.21B | 5.29B | 3.44B | 3.40B | 12.03B | 9.67B | 10.33B | 9.69B | 21.52B | 21.19B | 22.17B | 19.09B | 16.71B | 15.50B | 18.42B |
| Total Liabilities | - | - | 7.68B | 7.97B | 8.44B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Current Liabilities | - | - | 2.75B | 2.76B | 3.32B | 4.17B | 4.21B | 4.53B | 5.40B | 6.17B | 6.87B | 4.79B | 4.84B | 4.93B | 7.40B | 8.14B | 8.39B | 8.27B | 6.80B | 6.81B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.65B | 1.86B | 1.80B | 2.08B | 2.63B | 3.42B | 3.59B | 3.76B | 3.80B | 3.52B | 3.48B | 4.02B | 3.95B | 6.21B | 8.36B | 8.52B | 7.16B | 6.69B | 6.42B |
| Investing Cash Flow | -3.45B | -567.40M | -942.94M | -2.29B | -5.85B | -1.89B | -552.50M | -3.44B | -14.95B | -5.24B | -843.40M | -2.95B | -1.24B | -21.24B | -12.99B | -2.23B | -7.08B | -1.98B | -1.20B |
| Financing Cash Flow | 1.71B | -1.12B | 407.23M | 116.80M | 2.09B | -388.40M | -1.61B | -218.20M | 9.05B | 2.04B | -3.10B | -797.00M | 16.36B | 1.01B | 1.29B | -2.57B | -273.00M | -8.38B | -2.96B |
| Capital Expenditure | -162.07M | -193.78M | -175.44M | -191.10M | -334.50M | -458.30M | -538.10M | -465.40M | -512.90M | -589.60M | -570.70M | -584.00M | -636.00M | -791.00M | -1.24B | -1.12B | -1.38B | -1.39B | -1.16B |
| Free Cash Flow | 1.48B | 1.67B | 1.63B | 1.89B | 2.29B | 2.96B | 3.05B | 3.29B | 3.29B | 2.93B | 2.91B | 3.44B | 3.32B | 5.42B | 7.12B | 7.40B | 5.78B | 5.30B | 5.26B |
| Share Buybacks | 117.49M | 74.17M | 0 | - | 0 | 648.40M | 0 | 0 | - | - | - | - | - | - | - | 0 | 0 | 5.98B | 3.09B |
| Dividends Paid | 34.27M | 38.26M | 41.72M | 52.20M | 61.30M | 86.40M | 52.10M | 227.70M | 354.10M | 399.80M | 378.30M | 433.00M | 527.00M | 615.00M | 742.00M | 818.00M | 821.00M | 768.00M | 878.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 46.8% | 48.2% | 51.0% | 50.8% | 51.6% | 51.1% | 53.2% | 53.8% | 55.3% | 55.2% | 55.8% | 55.7% | 56.0% | 61.4% | 60.8% | 58.7% | 59.5% | 59.1% |
| Operating Margin % | 15.8% | 14.7% | 13.7% | 16.3% | 16.3% | 17.3% | 17.1% | 15.9% | 15.0% | 16.2% | 16.6% | 17.9% | 18.3% | 19.0% | 25.7% | 28.3% | 21.8% | 20.4% | 19.1% |
| Net Margin % | 12.4% | 10.4% | 11.0% | 14.3% | 13.5% | 13.1% | 14.7% | 20.2% | 23.3% | 15.1% | 16.1% | 15.5% | 16.8% | 16.4% | 25.9% | 27.1% | 19.9% | 16.3% | 14.7% |
| ROE % | - | 13.4% | 9.9% | 13.1% | 12.9% | 12.6% | 12.0% | 11.1% | 14.2% | 11.1% | 9.5% | 9.4% | 9.9% | 9.2% | 14.2% | 14.4% | 8.9% | 7.9% | 6.9% |
| ROCE % | - | 12.7% | 8.6% | 10.8% | 10.2% | 11.0% | 10.4% | 6.5% | 5.1% | 7.1% | 6.1% | 7.1% | 5.7% | 6.2% | 8.5% | 9.9% | 6.8% | 6.9% | 6.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.30% | 51.64M | $10.28B |
| 2 | Vanguard Capital Management LLC | 5.81% | 41.13M | $8.19B |
| 3 | State Street Corporation | 3.94% | 27.89M | $5.55B |
| 4 | FMR, LLC | 3.18% | 22.53M | $4.49B |
| 5 | JPMORGAN CHASE & CO | 2.39% | 16.92M | $3.37B |
| 6 | Price (T.Rowe) Associates Inc | 2.17% | 15.35M | $3.06B |
| 7 | Wellington Management Group, LLP | 2.09% | 14.77M | $2.94B |
| 8 | Geode Capital Management, LLC | 2.00% | 14.15M | $2.82B |
| 9 | Capital International Investors | 1.98% | 14.01M | $2.79B |
| 10 | Vanguard Portfolio Management LLC | 1.97% | 13.95M | $2.78B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DHR
Why Danaher (DHR) Stock Rose Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTFBZV24yRXVIZVpwOF9CN3BuNXVUa2JVOU1tazQxRDAzUV83TXVPVkk5TzRVcUEzb3BzaFpobnA0elQ2cTd6R0M2alphV09lM2pRdVVjY3JZd2FWUm5pOGJKYzE0ZzdZZ2dNSTAySTJ5TGNqZjRiMTRUUUY1TQ?oc=5" target="_blank">W…
Danaher (DHR) Stock Weighs Mixed Valuation Signals After Recent Price Rebound - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOVXpJeHNKTlYzQTR6Wkg4dFdWbTRydFFKWlBfOE1YV0lOdnlqVF9LWll0Smw3S1NLbHRBTzNDOUJaSzhCQ2txVW9qRTY3OFZvRzh0V0tDU25BekNuMGJFS2h3Z1MxMWpHb3NocTJaUVlQS1NqUXZwN3pJNGs0d3diR2VYVVVCZnUzX0VIQ0…
Lab-products maker StatLab set to join Danaher’s Leica - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQYm1HS3pSNGlYRWx0T3l0N0JBam1lVk9DVWxJYS1OX3dpQ1pOemZQSUZURlFURlB0RzJ5WlVvb0FLZ0ZVdnNjVjlPT0FFb1BYa3Z1SW5Hb0lSTEN1VnpjUUd0MUVJQVFwSjhSYTN1MndDSVZKMTAxczRyUTUydGNya0N6RmtxMmFrazZoN1…
Danaher (DHR) Stock Weighs DCF Upside Against Premium P/E After Recent Bounce - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNY3A3UEZLS3QtMUc0SVZaWjhPeWpfeGNwVGxpWTFPcDhwdURCR0FZZHJoNlhGY1haZjNnemJzcnZRVzJuR2xhQlNUT2w1SExtYzlWSFJiQlhFREwzSjZQb19TSHVYOXlwWGxWb1hSSjR1QmRBYUw0Si1HNTRVR0dRQjRzaWtidEN1Nmtvbk…
Danaher Is Getting Better, But The Stock Still Isn't Cheap (NYSE:DHR) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNbUJQd2dnaUNhWFplV2RQd190Wnp0NTZNRDJBTEoza0tHcG1jNFlUN2tvM0JRXzFCSU1JLXFra2UzMXM1dmJZbjFkY21WaVhUZ1NvWU1FRHhBLWQzc1NLTGYxcmk2TW5Pc0IweUZ4RER2OHZ0dXNna3hpNmN0Z09tWTRkWXBhTGJqQXBfQy…
Danaher (NYSE: DHR) Stock price Drops 22% In 2026 As $9.9 Billion Masimo Deal Reshapes The Investment Case - foreignpolicyjournal.com
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQZl9ieDZYUlJzWmRxd3FfdGtqZzJqbHNoZWNGY3FYZ192Qzh2Y1UwTTFxNDJNNTFLcW51dXBrcGZDS2wtZi1tV1JFVXB6MWxCWGo1VG5fQW9lbUtzUHQ2SlFJVlRwcGdCV1JDVzZ2QkpaMV84NlRSeGdrbzJyeVFYUUxMdk52OE9ZTWJJVW…
DHR — Frequently Asked Questions
What is the current share price of Danaher Corporation (DHR)?
As of 2026-07-15 16:51 PDT, Danaher Corporation (DHR) trades at $200.79 on NYSE. Its 52-week range is $161.57 to $241.04.
What is the market capitalisation of DHR?
Danaher Corporation (DHR) has a market capitalisation of $142.11B on NYSE.
What is the P/E ratio of DHR?
DHR trades at a trailing price-to-earnings (P/E) ratio of 39.06. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 2.66.
Does DHR pay a dividend?
Danaher Corporation (DHR) currently offers a dividend yield of 0.80%.
What is the return on equity (ROE) of DHR?
DHR has a return on equity (ROE) of 7.08%. Its return on capital employed (ROCE) is 6.12%.
Is DHR a good stock to buy?
This page provides a data-driven analysis of Danaher Corporation (DHR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.